Selective Small-Chemical Inhibitors of Protein Arginine Methyltransferase 5 with Anti-Lung Cancer Activity by Kong, Gui-Mei, Yangzhou University (Author) et al.
RESEARCH ARTICLE
Selective small-chemical inhibitors of protein
arginine methyltransferase 5 with anti-lung
cancer activity
Gui-Mei Kong1, Min Yu2, Zhongping Gu3, Zhi Chen4, Rui-Ming Xu4, Deon O’Bryant5,
Zhengxin Wang5*
1 Medical School of Yangzhou University, Yangzhou, China, 2 School of Life Sciences, Yunnan University,
Yunnan, China, 3 Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University,
Xi’an, China, 4 National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of




Protein arginine methyltransferase 5 (PRMT5) plays critical roles in a wide variety of biologi-
cal processes, including tumorigenesis. By screening a library of small chemical com-
pounds, we identified eight compounds that selectively inhibit the PRMT5 enzymatic
activity, with IC50 values ranging from 0.1 to 6 μM. Molecular docking simulation and site-
directed mutagenesis indicated that identified compounds target the substrate-binding site
in PRMT5. Treatment of lung cancer cells with identified inhibitors led to inhibition of the
symmetrical arginine methylation of SmD3 and histones and the cellular proliferation. Oral
administration of the inhibitor demonstrated antitumor activity in a lung tumor xenograft
model. Thus, identified PRMT5-specific small-molecule inhibitors would help elucidate the
biological roles of PRMT5 and serve as lead compounds for future drug development.
Introduction
Protein arginine methyltransferase (PRMT) enzymes transfer a methyl group from S-adeno-
sylmethionine (AdoMet) to the arginine side-chains in histones and other proteins [1–5].
PRMT enzymes are evolutionarily conserved in eukaryotes and can be divided into types I
through IV based on their patterns of arginine methylation [6]. Type I PRMTs modify proteins
by the catalysis of asymmetric NG,NG-dimethylarginine, whereas type II enzymes catalyze the
formation of symmetric NG,NG-dimethylarginine. Type III PRMTs catalyze the formation of
NG-monomethylarginine, and type IV PRMTs modify the delta nitrogen atom of the arginine
residue. All PRMTs have a common catalytic (methyltransferase) domain consisting of a
highly conserved core region of around 310 amino acid residues and subdomains important
for binding to AdoMet and to the substrate [7–10]. The individual PRMT family members dif-
fer in unique N-terminal or/and C-terminal regions, which contain distinct domain motifs
and perform different functions. PRMTs methylate histones, transcription factors and tran-
scriptional cofactors to regulate gene expression. Many PRMT substrates are associated with
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RNA; arginine methylation has been implicated in mRNA splicing, transport, and turnover
[2]. Studies have also indicated that PRMTs may play important roles in signal transduction as
well as protein nucleocytoplasmic shuttling. Because protein arginine methylation is an impor-
tant posttranslational modification process involved in essential cellular functions, deregula-
tion of PRMTs or their substrates contributes to several different pathogenic processes
including those in cancer and cardiovascular disease [4].
Protein arginine methyltransferase (PRMT5), the major type II methyltransferase [11], has
been implicated in diverse cellular and biological processes, including transcriptional regula-
tion [4,12,13], RNA metabolism [2,14], ribosome biogenesis [15], Golgi apparatus structural
maintenance [16], and cell cycle regulation [12]. In mammalian cells, PRMT5 localizes to both
the cytoplasm and the nucleus and methylates multiple histones and nonhistone proteins [2].
In the nucleus, PRMT5 has been found in the SWI/SNF and nucleosome remodeling and dea-
cetylase chromatin-remodeling complexes [17,18], where it can methylate histones as well as
transcription factors or regulators [4,12,13] and inhibit cell growth [19]. In the cytoplasm,
PRMT5 forms a 20S protein arginine methyltransferase complex, termed “methylosome,” con-
sisting of spliceosomal snRNP Sm proteins, PRMT5, pICln, and WD repeat protein (WDR77/
MEP50/WD45/p44) [20–22]. In this complex, PRMT5 methylates Sm proteins [20,23] and
such methylation increases the binding affinity of these Sm proteins for the survival motor
neuron (SMN), the spinal muscular atrophy disease gene product [24,25]. Subsequently,
PRMT5 and SMN complexes cooperate to load the Sm proteins onto U snRNAs, forming U
snRNPs [26]. Also in the cytoplasm, PRMT5 is essential for cell proliferation [19,27]. The
importance of PRMT5 in cancer is demonstrated by its upregulation in several human malig-
nancies [28] and essential role in growth of lung cancer cells and tumor xenografts [19,27].
Small-molecule inhibitors of PRMTs have been used to elucidate the biological roles of argi-
nine methylation. As an AdoMet analog, sinefungin competes for AdoMet binding and inhib-
its the activity of all AdoMet-dependent methyltransferases, including PRMTs [29]. Removal
of the methyl group from AdoMet generates S-adenosylhomocysteine, which also acts as a
methyltransferase inhibitor. Methylthioadenoine has been reported to inhibit methyltransfer-
ase activity via AdoMet catabolism; however, these inhibitors and similar molecules are not
specific to the PRMT pathways as they inhibit other AdoMet-dependent enzymes. Non-nucle-
oside small-molecule inhibitors (arginine methylation inhibitors) of PRMTs were identified by
Bedford and coworkers by screening a chemical compound library [29]. A few PRMT5-selec-
tive inhibitors have been discovered using various screening methods or by creating analogs to
arginine methylation inhibitors [30]. These inhibitors selectively inhibited PRMT5 activity as
well as growth of some cancer cells or tumor xenografts. We performed an ELISA-based
screening method and identified eight PRMT5-selective inhibitors. Identified compounds
inhibited growth of lung cancer cells and lung tumor xenografts in the nude mouse.
Materials and methods
Human subject research
The study does not involve human subjectives.
Animal research
Nude mice were used for the study. The Morehouse Medical School Institutional Animal Care
and Use Committee approved all of the experimental procedures. Mice were handled in accor-
dance with the guidelines published in the National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
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Chemicals
The DIVERset chemical compound library containining10,000 individual compounds from a
diverse collection of synthetic chemicals was purchased from ChemBridge Corporation (San
Diego, CA). All compounds meet the high quality standard of 100% identification by NMR
and/or LC-MS and have a purity level of at least 90%. Eight identified compounds and one
analogue compound (100 mg/each compound) were also purchased from ChemBridge Corpo-
ration. These nine compounds meet the high quality standard of 100% identification by NMR
and LC-MS and have a purity level of at least 95%.
Protein expression and purification
Human PRMT1, PRMT3, PRMT5, SmD3, and E2F1 cDNAs were subcloned into pET15d
(Novagen). These plasmids were transfected into BL21(ED3) cells. His6x-tagged proteins were
expressed and purified using Ni-NTA Agarose (QIAGEN) as reported [19]. Histones H2A,
H2B, H3, and H4 were purified form HeLa cells as reported elsewhere [31]. PRMT5 and
WDR77 were co-expressed in bacteria and purified as a stoichiometric complex of two poly-
peptides as reported previously by us [19]. The recombinant human histones H4 and H2A
were purchased from Sigma-Aldrich.
Screening for compounds
Ten-thousand small-molecule compounds from a DIVERSet library (ChemBridge) were
screened as follows: High-binding 96-well plates (Fisher Scientific) were coated with 100 ng of
recombinant SmD3 (the substrate) at 4 oC overnight. After blocking with 5% BSA for 30 min
at room-temperature, PRMT5-WDR77 (800 ng) was added to each well. DIVERSet compounds
were then transferred to individual wells to a final concentration of 20 μM. The enzyme reac-
tion was initiated by the addition of the methyl donor (AdoMet, 10 μM). Reaction mixtures
were incubated for 3 h at 30 oC. The wells were then washed twice with TBST (25 mM Tris
[pH 7.5], 150 mM NaCl, 0.1% Tween 20) and blocked in TBST containing 2% BSA for 30 min.
The methylarginine-specific primary antibody ab412 (Abcam) (1:1,000) and secondary anti-
body (anti-mouse IgG-peroxidase at 1:10,000; Fisher Scientific) were added to each well and
the mixtures were incubated at room-temperature for 1 h. After three washes with TBST, 0.1
ml of 3,30,5,50-tetramethylbenzidine (TMB) substrate (0.1 mg/ml) was added to each well.
Wells were incubated for 5 min in the dark at room-temperature and the reaction was stopped
by addition of 0.1 ml of 2 M H2SO4 per well. Potential “hits” were compounds associated with
at least a 90% reduction in optical density at 450 nm (in duplicate).
Radioactive methyltransferase assay
Methylation reactions were performed as previously described with a few modifications
[19,31]. Reaction mixtures (40 μl) containing 1.2 μg of PRMT5, 98 ng of PRMT1 or 98 ng of
PRMT3; 2 μg of SmD3 or histones; 1 μCi of S-[methyl-3H]adenosylmethionine (H3-AdoMet;
PerkinElmer); and 5 μM AdoMet were incubated in 50 mM Tris-HCl (pH 7.5)–1 mM EGTA–
1 mM EDTA at 30˚C for 2 h. Reaction mixtures (20 μl) were boiled in 5 μl of 5x SDS sample
buffer and separated on a 15% polyacrylamide gel. Gels were fixed for 30 min in 40% metha-
nol–10% acetic acid, incubated in 20 ml of Amplify (Amersham Life Science) for 10 min, dried
and exposed to X-ray film at -80˚C. IC50 was calculated by linear regression analysis of percent
inhibition. The other half (20 μl) of each reaction mixture was spread onto DE81 chromatogra-
phy paper discs (Whatman). The paper discs were washed 4 times with 50 mM NaHCO3 and
dried. The amounts of methylated products were quantified by liquid scintillation.
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Molecular docking
The program Glide [32,33] was used to dock all of the designed compounds into the binding
site of PRMT5 as well as PRMT1. In the docking process, the crystal structure of PRMT5 (PDB
code 3UA3) and PRMT1 (PDB code 3Q7E) were used, respectively. The water molecules were
deleted. Target protein protonation was performed with the pprep script in Glide. Glide con-
structed a grid that defined the ligand-binding site search region which was centered on the
co-crystallized S-Adenosyl-L-homocysteine (SAH) in the complex structures, respectively.
The grid was defined as an enclosed box with similar size of SAH in all three dimensions. For
the docking runs, the extra precision (XP) docking mode was selected. The compounds in
mol2 format were transferred into mae format with the mol2convert script and then docked
flexibly into the binding site. The pose with the best GlideScore for each ligand was saved for
further analysis.
Time-dependent inhibition assay
Different amounts of compound C2 or C5 were present in the final methylation reaction mix-
tures with 1.2 μg of PRMT5, 5 μM AdoMet, 2 μCi of H3-AdoMet and various concentrations
of SmD3. After a 10-, 20- or 30-min incubation at 30 oC or no incubation, the reaction mix-
tures were spread onto DE81 chromatography paper discs and the amounts of methylated
products were quantified by liquid scintillation. Amounts (counts per minute [cpm]) of meth-
ylated products and incubation time (minutes) were plotted and reaction velocity (cpm per
minute) was deduced.
HPLC chromatography
Waters 2695 HPLC System and a C18 column (Symmetry, 3.6 x 75 mm) were used. The col-
umn was equilibrated with 10% acetonitrile and eluated with a linear gradient from 10% aceto-
nitrile to 100% acetonitrile in 60 min. Compounds were dissolved in 10% acetonitrile and the
purchased compounds (ChemBridge) were used as the standards.
Cell culture and the treatment with compounds
Lung cancer A549 (ATCC) and PC14 (ATCC) cells were cultured in minimum essential me-
dium (Cellgro) with 10% (v/v) fetal bovine serum (FBS) (HyClone), 2% vitamins, 1% L-glu-
tamine, 1% non-essential amino acids and 1% sodium pyruvate. For the treatment with
identified compounds, cells (2, 000 cells/well) were seeded in 24-well plates in the medium
containing 2% FBS. The fresh medium containing identified compounds was added 24 hours
later. Cells were cultured for various times in a CO2 incubator and the cell numbers were
counted. Each experiment was performed in triplicate.
Histone isolation
Histones were purified as reported previously [34]. Briefly, cells (1–5 x 106) or lung tumors
(10–100 mg) were lysated using a glass dounce in 1 ml of 1x Passive Lysis Buffer (Promega)
and nuclear pellets were collected by centrifugation at 3,000 rpm for 5 min at 4 oC. The super-
natant was discard and the pellets were washed with 1 ml of 1x Passive Lysis Buffer. Nuclear
pellets were resuspended in 0.4 ml of the buffer (10 mM Trs-HCl, pH7.9, 0.2 mM EDTA, 1
mM DTT, 20% glycerol, 0.42 M KCl) and incubate for 30 min on ice, and centrifuged at
12,000 rpm for 10 min at 4 oC. The supernatant (histones extract) was transferred to a new
tube and histones were precipitated by 20% trichloroacetic acid.
PRMT5-inhibitors with anti-lung cancer activity
PLOS ONE | https://doi.org/10.1371/journal.pone.0181601 August 14, 2017 4 / 23
Western blot analysis
Protein extracts or histones (20 μg) were subjected to 10% or 15% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, respectively then transferred to Immobilon-P membranes
(Millipore). The blots were then probed for 2 hours with the primary antibody at dilutions of
1:500 (anti-symmetrical dimethylated arginine, SYM10, EMD Millipore), 1:1,000 (anti-B Raf,
ab65050, Abcam) or 1:1,000 (anti-PRMT5, Abcam). The blots were then incubated with a
horseradish peroxide-conjugated secondary antibody (1:5,000; Fischer Scientific) for 1.5 h.
Immunoreactive proteins were detected using an enhanced chemiluminescence detection sys-
tem (GE Healthcare) per the manufacturer’s instructions. Protein concentrations were deter-
mined using the Bradford protein assay reagent (Bio-Rad).
Measured serum concentrations of identified compounds
Male BALB/c mice (8–10 weeks old) were purchased from Charles River Laboratory and were
randomized for compound administration. Chemical compounds were dissolved in 0.1 ml of
0.5% (w/v) carboxymethycellulose (Sigma-Aldrich) plus 0.5% Tween 80 (Fisher Scientific) and
administrated by oral gavage at the dosage of 50 mg/kg or 100 mg/kg. Mice were sacrificed
and blood samples were collected immediately before (n = 5) and at 2 (n = 5), 4 (n = 5), 6
(n = 5) or 8 (n = 8) h after compound administration. Plasma samples were sent to the Phar-
maceutical Development Center at MD Anderson Cancer Center for LC-MS/MS assay to
determine compound concentrations.
Lung orthotopic tumors and the compound treatment
Six-week old nude mice were purchased from the National Cancer Institute and maintained in
a barred animal facility. Cell injection into the mouse lung was performed as described previ-
ously [35]. Mice were treated with vehicle [0.1 ml, 0.5% (w/v) carboxymethycellulose plus
0.5% Tween 80] by oral gavage or the compound dissolved in the vehicle (0.1 ml, 100 mg/kg)
for 21 days. The lungs of the mice were then removed, fixed with formaldehyde and embedded
in paraffin. Paraffin-embedded lung tissue sections (4 μm) were stained with H&E and evalu-
ated for tumors. The tumor areas in lungs were quantified using the ImageJ software program
(NIH).
Statistical analysis
Data are presented as the means of three independent experiments ± the standard deviation. A
2-tailed unpaired Student t-test was used to determine whether differences between control
and experimented samples were statistically significant. , p<0.05; , p<0.01; , p<0.001. P
values less than 0.05 were considered statistically significant.
Results
Screening for PRMT5 inhibitors
Cellular spliceosome protein SmD3 was methylated by PRMT5 in vitro and in vivo [23]. Mouse
monoclonal antibody (ab412 [Abcam]) reacts with NG-monomethyl and NG-NG-dimethyl argi-
nine and does not recognize unmodified arginine. This antibody was used to establish an
enzyme-linked immunosorbent assay (ELISA)-based screen for small molecule inhibitors of
arginine methylation of SmD3 by PRMT5. The recombinant SmD3 was immobilized on a
96-well plate and incubated with the human recombinant PRMT5-WDR77 complex. Small
molecules were added to individual wells using a 12-channel pipette. The methylation reaction
was initiated by addition of the methyl donor (AdoMet). The arginine-methylated SmD3 was
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detected by the monoclonal antibody ab412 and a peroxidase-conjugated secondary antibody.
The screen was performed on 10,000 individual compounds from a diverse collection of syn-
thetic chemicals (DIVERset, ChemBridge). We identified eight compounds that dramatically
(>90% at the concentration of 20 μM) inhibited methylation of SmD3 by PRMT5 (Fig 1,
Table 1). Compounds C2 and C4 are structurally related to compounds C7 and C6, respectively.
These compounds are not structurally related to the known PRMT5 inhibitors [30]. The IC50
(concentrations required to inhibit enzyme activity by 50%) values of the compounds ranged
from 0.1 to 6 μM (Table 1). These compounds inhibited arginine methylation activity of
PRMT5 similarly to the PRMT5-WDR77 complex. We selected five compounds (C2, C5, C6,
C9, and C11) for further analysis.
Identified compounds selectively inhibited PRMT5
To determine whether the five compounds inhibit PRMT5 selectively, we examined their inhi-
bition of other PRMT isoforms (type I PRMTs), PRMT1 and PRMT3, using the radioactive
methyltransferase assay. The results are shown in Fig 2. The recombinant PRMT1 and PRMT3
were active when assayed against the SmD3 substrate (Fig 2A, lane 2). In contrast to dramatic
PRMT5 inhibition, none of the five compounds significantly inhibited SmD3 methylation by
PRMT1 or PRMT3 at concentrations up to 100 μM (Fig 2A, lanes 3–17). Similarly, the five
compounds inhibited PRMT5 methylation of recombinant histones H2A and H4 (Fig 2B) but
not PRMT1 methylation of histones (H2A, H3, and H4) or E2F1 (Fig 2C). Thus, the five com-
pounds have high specificity for PRMT5 inhibition.
Binding model analysis of inhibitor-enzyme interaction
To understand the structural basis of the identified compounds’ inhibition of PRMT5, we used
the program Glide to investigate the docking of the compounds to PRMT5. Each compound
was individually docked in Caenorhabditis elegans PRMT5 [10]. Docking results were analyzed
according to the lowest energy order. The docked ligands were found to distribute only in the
substrate-binding region and none of them overlapped with other regions, including the Ado-
Met-binding site. For example, compound C2 interacts with the Glu450 and Lys451 residues
in PRMT5 (Fig 3A) and compound C5 interacts with the Gly415, Glu450, Met478 and Glu499
residues (Fig 3B). The compound C6 interacts with the Glu450 and Tyr386 residues (Fig 3C).
Compound C9 interacts with the Glu499 residue (Fig 3D). The conserved Phe379 in the active
site of PRMT5 is critical for symmetric addition of methyl groups and changing the residue to
methionine (Met) converted PRMT5 to an enzyme that catalyzes both symmetric and asym-
metric dimethylation of arginine [10]. We noticed that the compounds seem to have an aro-
matic-aromatic interaction (aromatic stacking/π stacking) with Phe379. The aromatic ring of
compound C2, C5, C6, or C9 and the aromatic side chain of Phe379 are seen in an off-center,
parallel orientation (Fig 3), a position preferred for forming the noncovalent interaction of
aromatic stacking [36].
The inhibitory activity of the compounds may stem from this interaction. To test this possi-
bility, we conducted site-directed mutagenesis to mutate Phe225 in human PRMT5 (corre-
sponding to Phe379 in the C. elegans PRMT5) to Met. The mutated PRMT5 was expressed
in bacteria and purified by Ni-nitrilotriacetic acid (Ni-NTA) affinity chromatography (Fig
4A). The activity of the mutant PRMT5 was examined by the radioactive methyltransferase
assay. In agreement with a previous report [10], the mutation of Phe225 to Met significantly
enhanced the methylation activity of PRMT5 (Fig 4B). Mutation greatly decreased the ability
of the five compounds to inhibit the methyltransferase activity of PRMT5 (Fig 4C). The IC50
values for the mutant PRMT5 increased from 4.3 to 183 folds higher than those for the wild
PRMT5-inhibitors with anti-lung cancer activity
PLOS ONE | https://doi.org/10.1371/journal.pone.0181601 August 14, 2017 6 / 23
Fig 1. Chemical structures of identified chemical compounds.
https://doi.org/10.1371/journal.pone.0181601.g001
PRMT5-inhibitors with anti-lung cancer activity
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type PRMT5 (Fig 4D). These results suggest that the Phe residue interacts with the compounds
and that mutation of this residue decreases compound binding and inhibition capacity. The
results also can help explain the specificity of the compounds to PRMT5. However, the contri-
bution of this interaction to inhibition varies among the compounds. For example, compound
C2 interacts with three amino acid residues (Lys451, Glu450, and Phe379) (Fig 3A) with the
mutation of Phe to Met resulting in a 50-times higher IC50 (Fig 4C and 4D). In contrast, com-
pound C5 interacts with five amino acid residues (Gly415, Glu450, Met478, Glu499, and
Phe379) and mutation of Phe to Met increased IC50 only 4.3 times (Fig 4C and 4D), indicating
that Phe379 is less important for PRMT5 inhibition by C5.
Competitive inhibition
To understand the mechanism of inhibition of identified compounds, we analyzed the kinetic
pattern of inhibition using steady-state enzymatic measurements. The velocities of PRMT5
methylation of SmD3 were measured at several selected concentrations of compounds C2 and
C5 over a range of SmD3 concentrations. Plotted in the double-reciprocal format with 1/veloc-
ity versus 1/[SmD3] (Fig 5), the data demonstrate that compounds C2 and C5 are competitive
inhibitors with regard to the SmD3 substrate. The similar analysis revealed that compounds
C2 and C5 are not competitive inhibitors with regard to SAM. These results agree with the
binding model analysis showing that the compounds interact with the active site binding to
the protein substrate (Fig 3).
Identified compounds are cell-permeable and inhibit PRMT5 in lung
cancer cells
We then determined whether the identified compounds are cell-permeable. Lung cancer A549
cells were cultured in medium containing various concentrations of the respective compound
for 2 hr. Cells were harvested and washed with PBS. The compounds were extracted with ethyl
acetate from cells and analyzed by HPLC with a C18 column using the purchased compound
as the standard. Compounds C2, C5, C9 and C11 are cell-permeable (Fig 6A), which is consis-
tent with their tPSAs <140 angstroms square (Table 1). In contrast, C6 is not cell-permeable
(Fig 6A). The concentrations of compounds C5, C9 and C11 inside cells were even higher than
those in the medium (Fig 6A) indicating these compounds were accumulated inside of the
cells. We even noticed that the compound C5 crystalized inside the cells. The concentrations
of C5, C9 and C11 inside the cells decreased by about 2 folds within 10 h (Fig 6B), indicating
that these compounds are relatively stable inside the cells.
Table 1. List of some properties of identified compounds.
Sample ID ChemBridge ID Formular Molecular Weight LogSW tPSA IC50
C1 7554223 C18H15N5O3 349 -6.36 95.2 0.50
C2 7561729 C18H15CIN2O3 343 -5.26 64.4 0.10
C4 6244219 C17H15N3OS 309 -4.89 68.0 0.60
C5 7661491 C18H17N3O4 339 -3.62 93.2 0.75
C6 5790435 C23H26N4O 447 -5.93 34.7 0.50
C7 7494331 C15H11FN2O3S 318 -4.56 64.4 2.5
C9 7664243 C20H19N5O 345 -5.45 64.9 6.0
C11 7630081 C25H22N2O3 398 -7.83 70.6 0.30
C9a 9032604 C18H16N6 316 -4.31 81.6 0.70
https://doi.org/10.1371/journal.pone.0181601.t001
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Fig 2. Identified compounds selectively inhibited the methyltransferase activity of PRMT5. In vitro methylation reactions were performed with
recombinant PRMT5 (1.2 μg), PRMT1 (89 ng) or PRMT3 (89 ng); [H3]-AdoMet; and different substrates in the presence of identified compounds. A, Identified
compounds inhibited methylation of SmD3 by PRMT5. The recombinant SmD3 (2 μg) was used as the substrate in the absence (lane 2) or presence of 1, 10
or 100 μM compounds as indicated. Reaction mixtures were separated on an SDS–15% polyacrylamide gel and the gel was dried under vacuum and
exposed to film. Lane 1 shows the product of the reaction without the enzyme. B, Identified compounds inhibited methylation of histones H2A and H4 by
PRMT5. Recombinant histones H4 or H2A (1 μg) were used as substrates of PRMT5 in the methylation assay in the absence or presence of 100 μM
PRMT5-inhibitors with anti-lung cancer activity
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To test whether these compounds inhibit PRMT5 in cells, we chose three known substrates
(H2A, H4, and B-Raf) of PRMT5 [4,37] to analyze. A549 cells were cultured in the presence of
DMSO or three compounds (C5, C9 and C11). Histones and B-Raf were purified and submit-
ted for Western blot analysis with the antibody against the symmetrical dimethyl arginine
(SYM10, Millipore) to detect the status of their methylation. Consistent with published
compounds as indicated. Reaction mixtures were spread onto DE81 chromatography paper discs. After a wash, the amounts of methylated products on
discs were quantified by liquid scintillation. C, Identified compounds did not inhibit methylation of histones and E2F1 by PRMT1. PRMT1 was incubated with
purified histones (1 μg) or recombinant E2F1 (1 μg) as substrates in the absence (lane 2) or presence of 100 μM compounds as indicated. Reaction mixtures
were separated on an SDS–15% polyacrylamide gel and the gel was dried and exposed to film.
https://doi.org/10.1371/journal.pone.0181601.g002
Fig 3. The compounds interact with the substrate-binding region in PRMT5. Docking of compounds C2, C5, C6 or C9 in PRMT5. The amino acid
residues in PRMT5 likely to interact with compound C2, C5, C6 or C9 are indicated in yellow.
https://doi.org/10.1371/journal.pone.0181601.g003
PRMT5-inhibitors with anti-lung cancer activity
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Fig 4. The conserved phenylalanine residue in PRMT5 is critical for inhibition by the five compounds. A, DS-PAGE of recombinant wild type (WT)
and F225M mutant (MT) PRMT5. The gel was stained with Coomassie Brilliant Blue R250. A band corresponding to an unknown bacterial protein is
PRMT5-inhibitors with anti-lung cancer activity
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observations [4,37], arginine methylation in histone H2A, histone H4 and B-Raf was detected
(Fig 6C, lanes 1 and 5) which was significantly inhibited by the compound C5, C9, or C11
(lanes 2–4, 6). Thus, these compounds inhibit symmetrical arginine dimethylation of proteins
in cells.
Identified compounds inhibit growth of lung cancer cells
It has been demonstrated that PRMT5 and its enzymatic activity are required for growth of
lung cancer cells [19,27]. To test whether identified compounds (C5, C9 and C11) inhibit cell
growth, we cultured lung cancer (A549 and PC14) cells in the presence of DMSO or various
concentrations of identified compounds. All three compounds inhibited A549 cell growth in a
dosage- and time-dependent manner at sub μM concentrations (Fig 7A). Similarly, all three
compounds also inhibited PC14 cell growth (Fig 7B). Silencing PRMT5 expression inhibited
indicated (star). B, The F225M mutation increased the methytransferase activity of PRMT5. In vitro methylation reactions were performed with recombinant
wild type (lanes 2–4) or mutant (lanes 5–7) PRMT5 (1.2, 2.4 or 4.8 μg) and SmD3 (2 μg) as the substrate. C, The F225M mutation in PRMT5 decreased
inhibition of arginine methylation by the compounds. The reaction mixture contained SmD3 (2 μg); wild type or mutant PRMT5 (1.2 μg); and 1, 10 or 100 μM
compounds as indicated. D, The F225M mutation in PRMT5 decreased the IC50 values of the compounds, as determined by quantitation and analysis of
methylation assay results.
https://doi.org/10.1371/journal.pone.0181601.g004
Fig 5. Steady-state kinetic analysis of PRMT5 inhibition by compounds C2 and C5. Double-reciprocal plot of reaction velocities (cpm per
minute) versus concentrations of SmD3. Methylation reaction mixtures contained various concentrations of C2 (left) or C5 (right), various
concentrations of SmD3, 1.2 μg of PRMT5 and 5 μM AdoMet. The mixtures were incubated for different times and the amounts of methylated
products were quantified using DE81 paper and liquid scintillation. Reaction velocity was calculated as H3 incorporation (cpm) into SmD3 per
minute.
https://doi.org/10.1371/journal.pone.0181601.g005
PRMT5-inhibitors with anti-lung cancer activity
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Fig 6. Identified compounds inhibited cellular targets of PRMT5. A, The cellular permeability of identified compounds. Lung
cancer A549 cells were cultured in the presence of various concentrations of compounds for 2h and the compound concentrations in
the cell were determined by HPLC chromatography with a C18 column. B, The cellular stability of identified compounds. Lung cancer
A549 cells were cultured in the presence of compounds (20 μM) for 2 h and then the medium was removed. Cells were washed with
the medium and cultured for additional 5 or 10 h after the compounds were removed. The compound concentrations in the cell were
determined by HPLC chromatography with a C18 column. C, Identified compounds inhibited arginine methylation of histones and
B-Raf in A549 cells. A549 cells were grown in the presence of DMSO or compound C5, C9 or C11 (20 μM). Histones were purified and
analyzed by SDS-PAGE stained with Commassie blue (lanes 1–4, bottom) or by Western blot with anti-symmetric dimethyl arginine
antibody (SYM10) (lanes 1–4, top). B-Raf was immunoprecipitated with anti-B-Raf antibody from whole cell lysates and submitted for
Western blot analysis with anti-B-Raf (lanes 5 and 6, bottom) or anti-symmetric dimethyl arginine (lanes 5 and 6, top) antibody.
https://doi.org/10.1371/journal.pone.0181601.g006
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Fig 7. Identified compounds inhibited growth of lung cancer cells. A, Lung cancer A549 cells were cultured in the presence of
various concentrations (μM) of identified compounds and growth inhibition was determined by cell counting at various time points. B,
Lung cancer PC14 cells were cultured in the presence of DMSO or various concentrations of identified compounds and growth inhibition
PRMT5-inhibitors with anti-lung cancer activity
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growth of lung cancer cells by suppressing cellular proliferation and arrested the cell cycle at
the G1 phase [27]. Similarly, identified compounds also arrested the cell cycle at the G1 phase
(S2 Fig) and inhibited proliferation of lung cancer cells (S3 Fig).
Oral bioavailability of identified compound
The obtained 3 compounds (C5, C9, and C11) have characteristics of Lipinski’s rule-of-five,
which defines four physicochemical parameters found in a set of active drugs which made
them into phase II clinical trials [38]. We chose one compound (C9) to analyze its pharmaco-
kinetic parameters in the mouse. BALB/c mice were randomized and administrated com-
pound C9 (dissolved in 5% DMSO and 0.5% Tween 80) at dosages of 25, 50 and 100 mg/kg by
intraperitoneal (I.P.) injection. Mice were sacrificed and blood samples were collected at dif-
ferent time points after administration of compounds. The compound concentrations in
plasma samples were measured (S1 Fig). The results show that the compound was absorbed
quickly into the bloodstream and reached high plasma concentrations (38 μM at the dosage of
100 mg/kg). However, we observed the high toxicity of the compound in the mouse at the dos-
age of 100 mg/kg.
The oral route of administration is central for delivery of a large number of important
drugs in various therapeutic areas and is the most preferred dosage form for cancer treatment
[39]. We then administrated the compound C9 by oral gavage formulated in 0.5% (w/v) car-
boxymethycellulose plus 0.5% Tween 80. Fig 7D shows the time course of compound plasma
concentrations following oral administration. The maximal plasma concentration achieved at
the dosage of 100 mg/kg is 5.8 μM.
About 40% of compounds identified through high-throughput or combinatorial screening
approaches are poorly water-soluble [40–42]. Physicochemical properties (such as solubility
and permeability) are essential features for oral absorption of drug candidates [42,43]. The
poor solubility of drug candidates results in low oral bioavailability and low plasma concentra-
tions [40,44,45]. The low aqueous solubility (LogSW: -5.45) of C9 (Table 1) may lead to low
plasma concentrations. The docking result (Fig 3D) indicates that methyl (CH3-) and methoxy
(CH3O-) groups in C9 are not involved in the interaction with PRMT5. By searching the com-
pound library (www.hit2lead.com/search.asp) we found a compound without the methyl
(CH3-) group and with an amino group (-NH2) substituting the methoxy (CH3O-) group of
C9 (Fig 8A). The compound has higher (12.6-fold) aqueous solubility than C9 increase
(Table 1). As expected, the C9 analogue (C9a) inhibited PRMT5 activity and growth of lung
cancer cells with higher efficacy and has improved oral drug availability compared to C9 (Fig
8B, 8C and 8D). The IC50 (~1 μM) in the cell growth assay is lower than that (~ 6 μM) in the
methylation assay. This may reflect the fact that compound C9 is accumulated (by 5-fold)
inside cells (Fig 6A).
Compound C9a suppressed growth of lung tumor xenografts
We used the orthotopic lung tumor model to determine effects of the compound C9a on
growth of lung cancer xenografts. A549 cells were injected into the lung of nude mouse as pre-
viously reported by us [27]. Mice were randomized and divided into two groups: (a) control
mice (n = 5): administration of the vehicle [0.5% (w/v) carboxymethycellulose plus 0.5%
Tween 80] by oral gavage daily; (b) treated mice (n = 10): administration of the compound
was determined by cell counting 2 days post the compound treatment. C, The serum concentrations of compound C9 after oral
administration. Mice were sacrificed and blood samples were collected immediately before (0 h) and at 2, 4, 6 and 8h after compound
administration.
https://doi.org/10.1371/journal.pone.0181601.g007
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C9a in the vehicle at the dosage of 100 mg/kg by oral gavage daily. Mice were treated with the
compound C9a for 3 weeks after cell injection. The treatment retarded growth of mice (S4
Fig 8. The C9 analogue has improved PRMT5-inhibitory efficacy and oral drug availability. A, The chemical structure of the C9
analogue. B, Compound C9a inhibited methylation of SmD3 by PRMT5. The recombinant SmD3 (2 μg) was used as the substrate in the
absence (lane 5) or presence of 1, 10 or 100 μM compounds as indicated. Lane 1 shows the product of the reaction without the enzyme. C,
C9a has improved efficacy to inhibit lung cancer growth. A549 cells were cultured in the presence of various concentrations of C9 or C9a and
growth inhibition was determined by cell counting 2 days post the compound treatment. D, C9a has improved oral drug availability in the
mouse. Male BALB/c mice were randomized and administrated C9a by oral gavage and compound concentrations in blood samples were
determined.
https://doi.org/10.1371/journal.pone.0181601.g008
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Fig). Large, macroscopically visible tumors were found in the lungs of five control mice (Fig
9A, i—v). However, tumor sizes in the lungs of the treated mice significantly decreased (Fig
9A, vi—xi). The average tumor sizes (tumor area mean) in the control mice were 7.2-fold big-
ger than that of the lung tumors in mice treated with the compound C9a (Fig 9B).
Histones were purified from lung tumors and submitted for Western blot analysis with the
SYM10 antibody to detect the status of the symmetric dimethylarginine of histones. The argi-
nine methylation in histone H2A was significantly inhibited by the treatment (Fig 9C, lanes
3–5 versus lane 2). Thus, corresponding decreased levels of the symmetrical arginine dimethy-
lated PRMT5 substrate in tumors strongly suggested that the compound C9a ’s effect on lung
tumors was a direct consequence of PRMT5 inhibition.
Discussion
In the present study, we identified eight small chemical compounds that specifically inhibit
PRMT5. Identified compounds interact with the substrate-binding site of PRMT5 through the
π-π interaction with the unique Phe residue in PRMT5. This interaction contributes to the
selectivity of identified compounds against other PRMTs. Identified compounds were cell-per-
meable and inhibited growth of lung cancer cells, which was correlated well with inhibition of
symmetric dimerthylation of arginine-containing substrates. Oral administration of one com-
pound demonstrated antitumor activity in the lung tumor xenograft model, with 86% tumor
growth inhibition observed after 21 days of the treatment.
In this study, an ELISA-based methylation assay was used to screen a library of 10,000 small
chemical compounds. By this approach, we identified eight novel chemical compounds that
inhibit PRMT5 but not PRMT1 and PRMT3. More recently, a few studies reported small
chemical inhibitors specifically targeting PRMT5. Compounds CMP5 and HLCL-61 specifi-
cally inhibited PRMT5 rather than PRMT1, CARM1, or PRMT7 [46,47]. The dual PRMT5-
PRMT7 inhibitor (DS-437) is an AdoMet competitor and targets the cofactor-binding site in
PRMT5 with an IC50 value of 6 μM [48]. From several rounds of screening against a diversity
library with 370,000 small molecules and structural optimization, the PRMT5-specific inhibi-
tor EPZ015666 was obtained [49]. EPZ015666 shows outstanding selectivity against the other
PRMTs and promising potency (IC50 = 0.022 μM). This compound interacts with many of the
residues in PRMT5 that involved in peptide binding and form a π-π stacking interaction with
Phe327 [49,50]. The inhibitors reported here do not share the structural similarity with these
previously identified PRMT5-inhibitors. Although identified compounds are structurally
diversified they all target the same site in PRMT5 mainly through the π-π interaction with the
unique Phe379 residue in PRMT5.
We identified a set of genes whose expression was altered by silencing PRMT5 expression
in lung cancer A549 cells [51]. A549 cells were treated with C9a and EPZ015666 and expres-
sion of 6 identified PRMT5-regulated genes was analyzed. Inhibition of PRMT5 enzymatic
activity only affeted expression of genes whose expression was suppressed by PRMT5 but no
effect on expression of genes whose expression was up-regulated by PRMT5 (S5 Fig). This
result suggested that the PRMT5 enzymatic activity may be only required to supress but not to
activat gene expression. The future study would use genome-wide approach to determine
genes whose expression is affected by PRMT5 inhibitors.
PRMT5 has been shown to be upregulated in a number of different cancers and plays an
essential role in growth of various cancer cells [11,28]. Consistent with these observations,
PRMT5-inhibitors suppressed growth of lymphoma, AML, and MCL cells in tissue culture
[46,47,49]. More recently, EPZ015666 demonstrated antitumor activity in multiple MCL xeno-
graft models [49]. Previous studies used RNA interference technologies revealed an essential
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Fig 9. The compound C9a inhibited growth of lung tumor xenografts in nude mice. A, Lungs derived from mice injected with A549 cells treated with
the vehicle or C9a at the dosage of 100 mg/kg for 21 days. B, Mean size of tumors. C, The C9a treatment inhibited histone 2A (H2A) arginine methylation in
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role PRMT5 in growth of lung cancer cells and lung tumor xenografts [27]. We have shown in
this report that identified PRMT5-inhibitors inhibited growth of lung cancer cells in tissue cul-
ture and oral administration of compound C9a suppressed growth of lung tumor xenografts.
We noticed that compounds C9 and C9a contain a known kinase inhibitor motif (aminopyri-
midine), which exists in some inhibitors of cyclin-dependent kinases (CDKs) (S6A Fig shows
chemical structures of the CDK2/5 inhibitor, Roscovitine and CDK4/6 inhibitor, Polbociclib).
The retinoblastoma protein (Rb) is phosphorylated by CKDs in cells [52]. Rb is primarily
phosphorylated by CDK2 at the site T821 and by CDK4/6 at the site S811, which is inhibited
by Roscovitine and Palbociclib, respectively (S6B Fig, lanes 4 and 5). However, compounds C9
and C9a failed to inhibit such phosphorylation events in A549 cells (S6B Fig, lanes 2 and 3),
suggesting that compounds C9 and C9a inhibit growth of lung cancer cells not through target-
ing CDKs rather than a direct consequence of PRMT5 inhibition.
Collectively, identified compounds are powerful probes that could be used to understand
more about the biologic roles of PRMT5 and potentially assist in defining a therapeutic strat-
egy for lung cancer treatment.
Supporting information
S1 Fig. The serum concentrations of compound C9. The chemical compound was dissolved
in 5% DMSO-0.5% Tween 80. BALB/c mice (8–10 weeks old) were randomized and adminis-
trated the vehicle (0.1 ml) or compound C9 dissolved in the vehicle (0.1 ml) by intraperitoneal
(I.P.) injection at the dosage of 25, 50 or 100 mg/kg. Mice were sacrificed and blood samples
were collected immediately before (0 h, n = 5) and at 2 (n = 5), 4 (n = 5), 6 (n = 5) and 8
(n = 5) h after compound administration. Plasma samples were sent to the Pharmaceutical
Development Center at MD Anderson Cancer Center for LC-MS/MS assay to determine com-
pound concentrations.
(TIF)
S2 Fig. Identified compounds arrested cell cycle at the G1 phase. A549 cells were infected
with the lentivirus expressing non-target (NT) or PRMT5 shRNA as described previously by
us [27]. A549 cells were grown in the presence of DMSO or 20 μM of the compound C5, C9 or
C11 for 2 days. A, PRMT5 protein levels in A549 cells. Whole cell lysates were prepared and
submitted for Western blot analysis with anti-PRMT5 (top) or anti-actin (bottom) antibody.
B, Cell cycle distributions. Cells were harvested, washed with phosphate-buffered saline (PBS)
and fixed in 70% ethanol at 4 oC overnight. Cells were collected and stained with propidium
iodide (PI). The cell-cycle distributions were determined by flow cytometry analysis (BD
AccuriTM C6 Flow Cyometer).
(TIF)
S3 Fig. Identified compounds inhibited cellular proliferation. A549 cells were infected with
the lentivirus expressing NT or PRMT5 shRNA. A549 cells were grown in the presence of
DMSO or compound C5, C9 or C11 (20 μM) for 2 days. A, Bromodeoxyuridine (BrdU) (BD
Biosciences) incorporation assay. Cells were plated on a Chamber slide (BD falcon) and cul-
tured in the presence of 10 μM BrdU for 4 h. The BrdU-positive cells (brown) were detected
by immunostaining with the monoclonal anti-BrdU antibody (BD Biosciences) and observed
under a microscope. B, Percentage of BrdU-positive cells in control, PRMT5-silencing or com-
pound treated cells. The results represent the means of three independent experiments ± the
lung tumor xenografts. Histones were isolated from tumors and analyzed by SDS-PAGE stained with Commassie blue R250 (bottom) or by Western blot
with anti-symmetric dimethyl arginine antibody (SYM10) (top).
https://doi.org/10.1371/journal.pone.0181601.g009
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standard deviation. , P<0.001.
(TIF)
S4 Fig. The compound treatment retarded mouse growth. Mice body weights were mea-
sured before and after the treatment for 7, 14 and 21 days. The results represent the means of
body weights of five mice ± the standard deviation. , p<0.05.
(TIF)
S5 Fig. PRMT5 inhibitors selectively affect PRMT5-target genes in lung cancer cells. RNAs
were isolated from cells cultured in the presence of DMSO, EPZ015666 (Sigma-Aldrich)
(50 μM), or C9a (50 μM) for 24 hrs and submitted to RT-RCR analysis of gene expression in
cancer cell lines. Relative mRNA levels = mRNA in cells treated with PRMT5-inhibtor/mRNA
in DMSo-treated cells.
(TIF)
S6 Fig. The compounds C9 and C9a do not inhibit the cyclin-dependent kinases (CDKs).
A, Chemical structures of CDK inhibitors Roscovitine and Polbociclib (Selleckchem.com) and
compounds C9 and C9a. B, Western blot of protein extracts (10 μg) derived from A549 cells
treated (4 h) with DMSO (lane 1) or 20 μM of compound C9 (lanes 2), C9a (lanes 3), Roscov-
itine (lanes 4), or Polbociclib (lane 5) with anti-Rb pS811 (Abcam, ab109399), -Rb pT821
(Abcam, ab4787), -Rb (Abcam, ab24) or -actin (Sigma-Aldrich) antibody.
(TIF)
S1 Data. Raw data of cell cycle analysis. Cells were treated with compounds and the cell-cycle
distributions were determined by flow cytometry analysis (BD AccuriTM C6 Flow Cyometer).
(PDF)
S1 Table. Raw data of real-time PCR analysis. RNAs were isolated from cells and submitted
for real-time PCR analysis with gene-specific primers as indicated.
(XLSX)
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